Clavia Ruth Wooton-Kee

Dr. Clavia Ruth Wooton-Kee


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CWClavia Ruth Wooton-Kee
Clavia Ruth Wooton-Kee
MRMatthew Robertson
Matthew Robertson
YZYing Zhou
Ying Zhou
BDBingning Dong
Bingning Dong
ZSZhen Sun
Zhen Sun
AAAlli Antar
Alli Antar
Inactivating mutations in the copper transporterAtp7bresult in Wilson’s disease. TheAtp7b−/−mouse develops hallmarks of Wilson’s disease. The activity of several nuclear receptors decreased inAtp7b−/−mice, and nuclear receptors are critical for maintaining metabolic homeostasis. Therefore, we anticipated thatAtp7b−/−mice would exhibit altered progression of diet-induced obesity, fatty liver, and insulin resistance. Following 10 wk on a chow or Western-type diet (40% kcal fat), parameters of glucose and lipid homeostasis were measured. Hepatic metabolites were measured by liquid chromatography–mass spectrometry and correlated with transcriptomic data.Atp7b−/−mice fed a chow diet presented with blunted body-weight gain over time, had lower fat mass, and were more glucose tolerant than wild type (WT) littermate controls. On the Western diet,Atp7b−/−mice exhibited reduced body weight, adiposity, and hepatic steatosis compared with WT controls.Atp7b−/−mice fed either diet were more insulin sensitive than WT controls; however, fastedAtp7b−/−mice exhibited hypoglycemia after administration of insulin due to an impaired glucose counterregulatory response, as evidenced by reduced hepatic glucose production. Coupling gene expression with metabolomic analyses, we observed striking changes in hepatic metabolic profiles inAtp7b−/−mice, including increases in glycolytic intermediates and components of the tricarboxylic acid cycle. In addition, the active phosphorylated form of AMP kinase was significantly increased inAtp7b−/−mice relative to WT controls. Alterations in hepatic metabolic profiles and nuclear receptor signaling were associated with improved glucose tolerance and insulin sensitivity as well as with impaired fasting glucose production inAtp7b−/−mice.

22 September 2023 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
CWClavia Ruth Wooton-Kee
Clavia Ruth Wooton-Kee

23 May 2025 in Hepatology Communications
Verified
Journal Article
Open access
CWClavia Ruth Wooton-Kee
Clavia Ruth Wooton-Kee
HYHari K. Yalamanchili
Hari K. Yalamanchili
IMIslam Badr Ezzeldin Mohamed
Islam Badr Ezzeldin Mohamed
MHManal M. Hassan
Manal M. Hassan
KSKenneth DR Setchell
Kenneth DR Setchell
DMDavid D Moore
David D Moore
Background: Wilson disease (WD) is an autosomal recessive disorder that results in excessive hepatic copper, causing hepatic steatosis, inflammation, fibrosis, cirrhosis, and liver failure. Previous studies have revealed dysregulation of many farnesoid X receptor (FXR) metabolic target genes in WD, including the bile salt exporter pump, the major determinant of bile flow. Methods: We tested the hypothesis that the FXR-cistrome is decreased in Atp7b −/ − mice in accord with dysregulated bile acid homeostasis. Results: FXR binding within Atp7b −/ − mouse livers displayed surprising complexity: FXR binding was increased in distal intergenic regions but decreased in promoter regions in Atp7b −/ − versus wild-type mice. Decreased FXR occupancy in Atp7b −/ − versus wild-type mice was observed in hepatocyte metabolic and bile acid homeostasis pathways, while enrichment of FXR binding was observed in pathways associated with cellular damage outside of hepatocytes. Indeed, disparate FXR occupancy was identified in parenchymal and non-parenchymal marker genes in a manner that suggests decreased FXR activity in parenchymal cells, as expected, and increased FXR activity in non-parenchymal cells. Consistent with altered FXR function, serum and liver bile acid concentrations were higher in Atp7b −/ − mice than in wild-type mice. Comparison of bile acid profiles in the serum of WD patients with “liver,” “neurological,” or “mixed” disease versus healthy controls also revealed increases in specific bile acids in WD-liver versus healthy controls. Conclusions: We identified novel FXR-occupancy across the genome that varied in parenchymal and non-parenchymal cells, demonstrating complex FXR regulation of metabolic and hepatocellular stress pathways in Atp7b −/ − mice. Dynamic changes in FXR activity support our novel finding of altered bile acid metabolism in Atp7b −/ − mice and WD patients.

1 June 2025 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
JSJi Ho Suh
Ji Ho Suh
ICInyoung Cheon
Inyoung Cheon
HJHyun-Jung Jung
Hyun-Jung Jung
SLSung Ho Lee
Sung Ho Lee
MHMi Jeong Heo
Mi Jeong Heo
KKKang Ho Kim
Kang Ho Kim
Hepatic bile acid signaling plays a crucial role in coordinating systemic metabolism between the liver and other peripheral tissues. Our report demonstrates that, under bile acid-enriched conditions, activation of nuclear receptors CAR and PXR stimulate the expression of several putative hepatokines, including the orosomucoid gene family, which may exert regulatory effects in the liver and adipose tissue against metabolic disorders.

6 August 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
XCXi Chen
Xi Chen
HLHuiqiao Li
Huiqiao Li
YDYanru Deng
Yanru Deng
JMJieyi Meng
Jieyi Meng
SZShangang Zhao
Shangang Zhao
YZYi Zhu
Yi Zhu
4-Methylumbelliferone (4-MU) is the active component of hymecromone, a choleretic and antispasmodic drug with an excellent safety profile. In rodent studies, high doses of 4-MU are also used to inhibit the production of hyaluronan (HA), a biomarker of liver fibrosis. Further, 4-MU shows excellent efficacy in inhibiting liver fibrosis of different etiologies in animal studies, eliciting interest in its repurposing for this condition. However, 4-MU's mechanism of action, and whether it inhibits liver fibrosis by impeding HA synthesis remains unclear. Using several transgenic mouse models with HA overproduction or degradation in different types of liver cells, we found that both directions of perturbation reduced liver fibrosis levels. In addition, degrading HA via hyaluronidase PH20 overexpression impaired liver function, manifested by increased serum aminotransferase (ALT) activity levels. These findings challenge both the role of HA modulation in 4-MU's action and the strategy of targeting HA to treat liver fibrosis. Additional mouse models also excluded the possibility that 4-MU modulates intestinal farnesoid X receptor (FXR) to inhibit liver fibrosis. Ablation of gut microbiota partially abolishes 4-MU's anti-liver fibrosis effect. However, the anti-liver fibrosis effect of 4-MU was lost in the lower-dose group. Based on these findings, we argue that the lack of efficacy of 4-MU at a translatable dose and the lack of a precise mechanism that allows improvement of 4-MU's efficacy make 4-MU impractical for being repurposed as an anti-liver fibrosis treatment.

15 February 2023 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
KKKang Ho Kim
Kang Ho Kim
CWClavia Ruth Wooton-Kee
Clavia Ruth Wooton-Kee